Zealand Pharma to host conference call for Full-Year 2010 financial results
2/4/2011 10:23 AM EST
Zealand Pharma A/S
Investor News
Zealand Pharma to host conference call for Full-Year 2010 financial results
Investor News
No. 03/2011
4 February 2011
Zealand Pharma to host conference call for Full-Year 2010 financial results
Zealand Pharma A/S (NASDAQ OMX: ZEAL), a biopharmaceutical company dedicated to
the discovery and development of innovative peptide drugs, will announce
preliminary Full-Year 2010 financial results on 10 February 2011 at 14:00 (CET)
/ 13:00 (GMT) / 08:00 (EST).
On the day of results, David Solomon, President and CEO, and Mats Blom, CFO,
will host a conference call at 15:00 (CET) / 14:00 (GMT) / 09:00 (EST).
The conference call will be conducted in English and the dial-in numbers are:
DK +45 32 71 46 07
UK and international +44 (0) 145 255 5566
US +1 866 966 9439
Passcode for all participants: 42824017
An accompanying presentation will be available for download from the company's
website (ir.zealandpharma.com) approximately one hour before the event.
The conference call will also be webcast live from the company's website, and a
replay of the event will be available on ir.zealandpharma.com.
The printed Annual Report 2010 will be available 14 April 2011.
# # #
For further information, please contact:
Zealand Pharma A/S
David Solomon, President and Chief Executive Officer
Tel: +45 4328 1200
M:Communications
Mary-Jane Elliott / Emma Thompson / Amber Bielecka / Ulf Martensson
Tel: +44 20 7920 2330 / +46 8 407 22 43
About Zealand Pharma A/S
Zealand Pharma is a Danish biopharmaceutical company dedicated to the discovery
and development of innovative peptide drugs. The Company is based in Copenhagen
and joined the NASDAQ OMX Copenhagen in November 2010 trading under the ticker
symbol ‘ZEAL'.
Zealand Pharma targets diseases where it believes existing treatments fail to
adequately serve the medical needs of patients and the market potential for
improved treatments through the use of peptide drugs is high.
Zealand Pharma focuses on three therapeutic areas: metabolic (diabetes and
obesity), gastrointestinal and cardiovascular diseases. The Company's expertise
in peptide discovery, optimization and development has resulted in a strong and
growing pipeline of novel peptide drug candidates with favourable therapeutic
attributes.
Since 1999, Zealand Pharma's scientists have built a pipeline that includes
five compounds in clinical development, four of which have been out licensed,
two of these with major pharmaceutical companies (sanofi-aventis and Helsinn
Healthcare). All of Zealand Pharma's compounds emerged from the Company's own
drug discovery.
For more information please visit the Company's web site: www.zealandpharma.com.